As a Co-Founder of Aspiro Therapeutics, Stefano Guerra develops the overall medical strategy for the company’s lead therapeutic asset, including target patient populations, dosing regimens, and potential clinical endpoints.
Stefano trained as an adult pulmonologist and is an accomplished scientist with a strong track record in respiratory disease research and clinical epidemiology. Stefano’s extensive background includes significant experience in designing and conducting large-scale epidemiological studies. He has been instrumental in identifying genetic and environmental factors that influence the development and progression of respiratory diseases.
In his role at Aspiro, Stefano plays a key role in clinical development plans and prepares the company for interactions with regulatory agencies like the FDA, facilitating the approval process for the lead asset.